SLC5A2 and type 2 diabetes mellitus: Similarly, the 2018 American Association of Clinical Endocrinologists (AACE)/American College of Endocrinology (ACE) Comprehensive Type 2 Diabetes Management Algorithm also recommends GLP-1 receptor agonists and SGLT2 inhibitors as preferred add-on agents to metformin and lifestyle with no preference for a specific agent within each class [80].